J Erik Johnson
Overview
Explore the profile of J Erik Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vidunas E, Mathews A, Weaver M, Cai P, Koh E, Patel-Brown S, et al.
J Pharm Sci
. 2016 May;
105(7):2032-41.
PMID: 27233688
A recombinant Clostridium difficile expression system was used to produce genetically engineered toxoids A and B as immunogens for a prophylactic vaccine against C. difficile-associated disease. Although all known enzymatic...
2.
Clarke D, Nasar F, Chong S, Johnson J, Coleman J, Lee M, et al.
J Virol
. 2014 Apr;
88(12):6690-701.
PMID: 24696472
Unlabelled: In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vector expressing simian immunodeficiency virus (SIV) gag and human immunodeficiency virus type 1 (HIV-1) env antigens protected...
3.
Eyles J, Johnson J, Megati S, Roopchand V, Cockle P, Weeratna R, et al.
J Infect Dis
. 2013 Apr;
208(2):319-29.
PMID: 23596321
Background: We evaluated the immunological responses of African green monkeys immunized with multiple F and G protein-based vaccines and assessed protection against the Memphis 37 strain of respiratory syncytial virus...
4.
Johnson J, McNeil L, Megati S, Witko S, Roopchand V, Obregon J, et al.
Immunol Lett
. 2012 Dec;
150(1-2):134-44.
PMID: 23261719
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in infants, the elderly, and other high-risk individuals. Despite years of research in this field, there...
5.
Witko S, Johnson J, Kalyan N, Felber B, Pavlakis G, Sidhu M, et al.
J Virol Methods
. 2009 Nov;
164(1-2):43-50.
PMID: 19941901
Propagation-defective vesicular stomatitis virus (VSV) vectors that encode a truncated G protein (VSV-Gstem) or lack the G gene entirely (VSV-DeltaG) are attractive vaccine vectors because they are immunogenic, cannot replicate...
6.
Johnson J, Coleman J, Kalyan N, Calderon P, Wright K, Obregon J, et al.
Vaccine
. 2009 May;
27(22):2930-9.
PMID: 19428903
Recombinant vesicular stomatitis viruses (rVSVs) are being developed as potential HIV-1 vaccine candidates. To characterize the in vivo replication and dissemination of rVSV vectors in mice, high doses of a...
7.
Cooper D, Wright K, Calderon P, Guo M, Nasar F, Johnson J, et al.
J Virol
. 2007 Oct;
82(1):207-19.
PMID: 17942549
Recombinant vesicular stomatitis virus (rVSV) has shown great potential as a new viral vector for vaccination. However, the prototypic rVSV vector described previously was found to be insufficiently attenuated for...
8.
Coleman J, Johnson J, Clarke D
Biotechniques
. 2007 Oct;
43(3):369-71.
PMID: 17907580
No abstract available.
9.
Coleman J, Ogin-Wilson E, Johnson J, Nasar F, Zamb T, Clarke D, et al.
J Virol Methods
. 2007 Mar;
143(1):55-64.
PMID: 17382412
Assessment of in vivo viral replication of live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine vector candidates encoding HIV gag requires comprehensive preclinical safety studies, and development of sensitive assays...
10.
Clarke D, Nasar F, Lee M, Johnson J, Wright K, Calderon P, et al.
J Virol
. 2006 Dec;
81(4):2056-64.
PMID: 17151112
A variety of rational approaches to attenuate growth and virulence of vesicular stomatitis virus (VSV) have been described previously. These include gene shuffling, truncation of the cytoplasmic tail of the...